<?xml version="1.0" encoding="UTF-8"?>
<p>Although PrEP for high-risk populations is now recommended by national or regional guidelines in the US [
 <xref rid="pone.0204138.ref007" ref-type="bibr">7</xref>, 
 <xref rid="pone.0204138.ref008" ref-type="bibr">8</xref>], Australia [
 <xref rid="pone.0204138.ref009" ref-type="bibr">9</xref>], and a number of other countries [
 <xref rid="pone.0204138.ref010" ref-type="bibr">10</xref>â€“
 <xref rid="pone.0204138.ref012" ref-type="bibr">12</xref>], as well as in international WHO guidelines [
 <xref rid="pone.0204138.ref013" ref-type="bibr">13</xref>], access to PrEP remains limited. In the US, universal PrEP access has not yet been achieved; only some locations (e.g., San Francisco, New York City and Seattle) have reported significant progress [
 <xref rid="pone.0204138.ref014" ref-type="bibr">14</xref>]. While PrEP is expected to have a substantial impact on HIV epidemics worldwide [
 <xref rid="pone.0204138.ref015" ref-type="bibr">15</xref>], the uptake of PrEP remains limited, partly due to the high cost of TDF/FTC [
 <xref rid="pone.0204138.ref016" ref-type="bibr">16</xref>] in settings where cheaper generics are not yet available.
</p>
